{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:42:49Z","timestamp":1770522169393,"version":"3.49.0"},"reference-count":17,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2006,7,4]],"date-time":"2006-07-04T00:00:00Z","timestamp":1151971200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Rosacea is a skin problem not uncommonly encountered world\u2010wide. There is a need for an effective and well\u2010tolerated treatment for this disease.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the efficacy and side\u2010effects of zinc sulfate in rosacea in a randomized, controlled, double\u2010blind trial.<\/jats:p><jats:p><jats:bold>Patients and methods\u2002<\/jats:bold> Patients with rosacea who attended the outpatient Clinic of Dermatology and Venereology in Baghdad Teaching Hospital were recruited into this study between October 2002 and August 2004. A disease severity score was calculated for each patient. The patients were randomly allocated to receive either zinc sulfate 100\u00a0mg or identical placebo capsules three times per day. Zinc sulfate and placebo capsules were given in a double\u2010blind manner. Following 3\u00a0months of starting the treatment, the patients crossed over, i.e. patients on placebo crossed over to zinc sulfate and those on zinc sulfate crossed over to placebo.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Twenty\u2010five patients with rosacea were included in this study: 16 (64%) females and nine (36%) males. Nineteen patients completed the study: 11 (58%) females and eight (42%) males. Patient age ranged from 21 to 64\u00a0years with a mean\u00a0\u00b1\u00a0SD of 48.2\u00a0\u00b1\u00a09.3\u00a0years. Duration of the disease ranged from 1 to 14\u00a0years with a mean\u00a0\u00b1\u00a0SD of 4.4\u00a0\u00b1\u00a03.2\u00a0years. In the group started on zinc sulfate, the score before therapy ranged from 5 to 11 with a mean\u00a0\u00b1\u00a0SD of 8\u00a0\u00b1\u00a02.0. The mean started to decrease directly after the first month of therapy with zinc sulfate to a significantly lower level. After shifting to placebo treatment, the mean started to rise gradually in the fifth month but remained significantly lower than the levels before therapy. In the group started on placebo, the score before therapy ranged from 5 to 9 with a mean\u00a0\u00b1\u00a0SD of 7\u00a0\u00b1\u00a01.3. The mean remained high in the first 3\u00a0months of therapy while the patients were on placebo. After shifting to zinc sulfate, the mean started to decrease after the fourth month to significantly low levels. No important side\u2010effects were reported apart from mild gastric upset in three (12%) patients on zinc sulfate.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Zinc sulfate was found to be a good option in the treatment of rosacea, as it was safe, effective and lacking important side\u2010effects.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2006.02944.x","type":"journal-article","created":{"date-parts":[[2006,7,6]],"date-time":"2006-07-06T20:24:30Z","timestamp":1152217470000},"page":"857-861","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Oral zinc sulfate in the treatment of rosacea: A double\u2010blind, placebo\u2010controlled study"],"prefix":"10.1111","volume":"45","author":[{"given":"Khalifa E.","family":"Sharquie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafid A.","family":"Najim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala N.","family":"Al\u2010Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,4]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"784","volume-title":"Dermatology in General Medicine","author":"Plewig G","year":"1999"},{"key":"e_1_2_5_3_2","unstructured":"GreavesMW.Flushing and flushing syndromes rosacea and perioral dermatitis. In:ChampionRH BurtonJL BurnsDA et al.eds. Textbook of Dermatology 6th edn. Vol.3. Oxford:Blackwell Scientific Publications 1998:2099\u20132112."},{"key":"e_1_2_5_4_2","first-page":"404","volume-title":"Lever's Histopathology of the Skin","author":"Abell E","year":"1997"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","unstructured":"BamfordJT ElliotBA HallerIV.Tacrolimus effect on rosacea.J Am Acad Dermatol2004:107\u2013108.","DOI":"10.1016\/S0190-9622(03)02157-1"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00752.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04617.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/archderm.1985.01660080082019","article-title":"Perifolliculitis capitis abscendens et suffodiens (Hoffman): Complete healing associated with oral zinc sulphate","volume":"121","author":"Berne B","year":"1985","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_9_2","first-page":"166","article-title":"Acne: evolution of clinical practice and therapeutic management of acne between 1996 and 2000","volume":"13","author":"Dreno B","year":"2003","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_10_2","first-page":"125","article-title":"Rosacea 2000","volume":"66","author":"Hirsch RJ","year":"2000","journal-title":"Cutis"},{"key":"e_1_2_5_11_2","unstructured":"JohanYH.A therapeutic trial in rosacea of metronidazole and azithromycin.MSc Thesis.Iraq: College of Medicine University of Baghdad 2004."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01179.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01567.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(78)90274-X"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1179\/136485905X19900"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1998.tb01739.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200111000-00019"},{"key":"e_1_2_5_18_2","unstructured":"Al\u2010BaghdadiB.A possible useful effect of zinc carbonate in peptic ulceration.MSc Thesis.Iraq: College of Medicine University of Baghdad 1999."}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2006.02944.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2006.02944.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:17:10Z","timestamp":1696907830000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2006.02944.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1365-4632.2006.02944.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2006.02944.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]},"assertion":[{"value":"2006-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}